TB-500 + Ipamorelin Stack: Evidence, Mechanism Overlap, and Protocol

What Is TB-500 and How Does It Work?

TB-500 is the synthetic, commercially distributed name for Ac-SDKP, the four-amino-acid N-terminal fragment of thymosin beta-4 (Tβ4). Full-length Tβ4 is a 43-amino-acid protein encoded by the TMSB4X gene. The Ac-SDKP fragment drives most of the tissue-repair activity ascribed to the full peptide in animal models.

Actin Sequestration and Cell Migration

Tβ4 binds G-actin in a 1:1 molar ratio, preventing actin polymerization and keeping a pool of monomeric actin available for rapid cytoskeletal remodeling. This mechanism was characterized in a landmark study by Safer et al. Published in the Journal of Biological Chemistry and underpins TB-500's putative ability to accelerate cell migration into wound beds. [1]

Angiogenesis and Cardioprotection

Beyond actin, Tβ4 promotes angiogenesis by upregulating hypoxia-inducible factor-1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF). A 2004 study by Bock-Marquette et al. In Nature demonstrated that Tβ4 activated integrin-linked kinase (ILK), promoted cardiac progenitor cell survival, and reduced infarct size in a murine myocardial infarction model. [2] The effect size was meaningful: treated hearts showed roughly 20% less fibrotic tissue compared to saline controls, though translating rodent infarct-model data to human clinical outcomes requires significant caution.

Anti-Inflammatory Signaling

Ac-SDKP itself has been shown to inhibit transforming growth factor-beta 1 (TGF-β1)-driven fibrosis in renal tissue. A study in Hypertension by Peng et al. Reported that chronic Ac-SDKP infusion reduced collagen deposition by approximately 40% in a rat model of angiotensin II-induced fibrosis. [3] This anti-fibrotic action is mechanistically distinct from Ipamorelin's GH axis effects and is a primary reason practitioners combine the two peptides.

What Is Ipamorelin and How Does It Work?

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively binds the growth hormone secretagogue receptor type 1a (GHSR-1a). It was characterized in detail by Raun et al. In a 1998 paper in European Journal of Endocrinology, which established its high GH-release potency and minimal effect on cortisol or prolactin compared to earlier secretagogues like GHRP-6. [4]

GHSR-1a Selectivity and GH Pulse Amplitude

Ipamorelin's clinical appeal rests on its receptor selectivity. GHRP-6 and GHRP-2 both stimulate adrenocorticotropic hormone (ACTH) and cortisol release alongside GH. Ipamorelin does not do this at therapeutic doses. Raun et al. Showed that in pigs, Ipamorelin produced GH pulses 3- to 7-fold above baseline without statistically significant cortisol changes, a property not shared by GHRP-2 at equivalent GH-releasing doses. [4]

Downstream IGF-1 Production

GH released by Ipamorelin travels to the liver and stimulates insulin-like growth factor 1 (IGF-1) synthesis. IGF-1 is the effector molecule responsible for most anabolic and tissue-repair outcomes attributed to GH-axis stimulation. A study in the Journal of Clinical Endocrinology and Metabolism by Corpas et al. Documented that restoring physiologic GH pulsatility in older adults increased IGF-1 levels by 30 to 40%, which correlated with improvements in lean body mass. [5] Ipamorelin mimics this pulsatile pattern, though no published human trial has measured this effect with Ipamorelin specifically.

Timing and the Somatostatin Gate

GH secretion is gated by somatostatin, which is highest postprandially. Administering Ipamorelin during a fasting window (at least 2 hours post-meal, or immediately pre-sleep) reduces somatostatin tone and allows a larger GH pulse. Missing this timing window blunts efficacy; practitioners routinely report 30 to 50% lower perceived recovery signals when subjects inject after eating, though this is observational data only.

Mechanism Overlap: Where TB-500 and Ipamorelin Converge

The two peptides do not share a receptor or a direct signaling node. Their convergence is functional rather than molecular.

Shared Tissue Repair Endpoint

Both peptides influence the same downstream outcome: faster repair of damaged connective tissue, muscle, and endothelium. Tβ4/TB-500 drives this from the bottom up through cell migration, actin dynamics, and local VEGF. Ipamorelin drives it from the top down through systemic IGF-1, which binds IGF-1R on fibroblasts and myoblasts and increases collagen synthesis and satellite cell activation. [6]

A 2019 review in Growth Hormone and IGF Research noted that IGF-1 and VEGF co-regulate angiogenesis in skeletal muscle repair, suggesting that co-stimulation of both pathways could produce additive rather than merely parallel effects. [7] "Additive" here is a mechanistic prediction, not a proven clinical outcome for this specific peptide pair.

Inflammation Resolution Timing

TB-500's anti-inflammatory and cell-migratory effects are most active in the early inflammatory and proliferative phases of wound healing (roughly days 1 to 7 post-injury). IGF-1-driven collagen remodeling is more active in the remodeling phase (weeks 3 to 12). This temporal offset means the two peptides may act in sequence rather than redundantly, which is the mechanistic rationale practitioners cite for running them concurrently.

No Direct Receptor Conflict

Because TB-500 operates through G-actin binding and integrin signaling while Ipamorelin operates through GHSR-1a, there is no known competitive binding, receptor downregulation, or pharmacokinetic interaction between them. This does not mean the combination is safe. It means the risk, if present, would arise from additive downstream effects (e.g., excessive IGF-1, aberrant angiogenesis) rather than from a drug-drug interaction at the receptor level.

What the Animal Evidence Shows

Skeletal Muscle and Tendon Repair

A 2010 study by Gupta et al. In Journal of Applied Physiology found that Tβ4 treatment accelerated skeletal muscle repair after cardiotoxin-induced injury in mice, with treated animals showing 35% more centrally nucleated (regenerating) myofibers at day 7 compared to controls. [8] No equivalent study has co-administered a GH secretagogue with Tβ4 in this model.

Cardiac Models

The Bock-Marquette 2004 Nature study referenced above remains the highest-cited animal evidence for Tβ4 cardioprotection. [2] For GH secretagogues, a separate line of research shows that GHRP-6 (structurally related to Ipamorelin) reduced myocardial infarct size in rats by approximately 30%, an effect attributed to anti-apoptotic GH-independent signaling through GHSR-1a directly in cardiac tissue. [9] Ipamorelin shares GHSR-1a affinity with GHRP-6, so this cardioprotective mechanism may apply, but no direct Ipamorelin cardiac study replicates the GHRP-6 findings.

The Evidence Ceiling

No peer-reviewed animal study has co-administered TB-500 (or full Tβ4) with Ipamorelin and measured outcomes. The stack's rationale is built by combining evidence from separate experiments, a form of mechanistic extrapolation that carries real uncertainty. Practitioners and patients who use this combination are operating ahead of published science.

Human Evidence and Evidence Gaps

What Human Data Exist for Each Peptide Individually

For full-length Tβ4, a Phase II trial (NCT00289770) investigated topical Tβ4 for corneal wound healing and reported a statistically significant reduction in time to corneal epithelial healing compared to vehicle. [10] This is the most rigorous human evidence for a Tβ4-based compound and involves a completely different route of administration (topical ophthalmic) than the subcutaneous injection used by TB-500 users.

For Ipamorelin specifically, no completed published Phase II or Phase III trial in healthy adults or athletes exists in the public literature as of July 2025. Phase I data filed with the FDA for Ipamorelin/CJC-1295 combinations remain proprietary to the sponsoring companies.

The RCT Gap for the Stack

Zero published randomized controlled trials have tested the TB-500 plus Ipamorelin combination in any population. Practitioner-reported outcomes circulate in clinical forums and patient communities, but these carry the same limitations as case series: no control arm, no blinding, and strong expectancy effects in performance-oriented populations.

The HealthRX medical team uses the following evidence-weighting framework for this stack. Mechanistic plausibility: high (two non-competing, convergent repair pathways). Animal evidence: moderate for each peptide individually, absent for the combination. Human RCT evidence: absent. Practitioner consensus: emerging but anecdotal. Risk profile: incompletely characterized, with the oncology signal being the principal unknown.

Protocol Considerations (Research Context Only)

These parameters reflect practitioner-reported and mechanism-derived ranges. They are not FDA-approved dosing instructions and are provided for educational purposes only.

TB-500 Dosing Approach

The most commonly cited loading protocol runs 2 to 2.5 mg subcutaneously twice per week for 4 to 6 weeks. Maintenance dosing is typically reduced to 2 mg once per week or once every two weeks. Reconstitution uses bacteriostatic water at 2 mL per vial; storage is at 2 to 8 degrees Celsius after reconstitution. Injection sites rotate across the abdomen or thigh subcutaneous tissue.

Ipamorelin Dosing Approach

Reported doses range from 200 to 300 mcg per injection, administered subcutaneously. Frequency varies from once daily (pre-sleep, fasted) to three times daily (morning fasted, post-training fasted, pre-sleep). The pre-sleep injection is considered the highest-yield timing because endogenous GH pulsatility peaks during slow-wave sleep, and Ipamorelin amplifies rather than replaces that pulse. [4]

Stack Sequencing

Practitioners typically inject the two peptides in separate syringes. No published pharmacokinetic data confirm whether co-administration alters absorption or half-life of either compound. TB-500's half-life in animal studies is estimated at 1.4 hours (intravenous) with tissue distribution extending considerably longer due to actin binding. Ipamorelin's plasma half-life in pigs was approximately 2 hours in the Raun et al. Characterization study. [4]

Cycle Duration and Off Periods

A common practitioner-cited cycle is 8 to 12 weeks total (4 to 6 weeks loading TB-500, then transitioning to maintenance while continuing Ipamorelin), followed by a 4- to 8-week off period. The rationale for off periods is receptor sensitivity maintenance for GHSR-1a, not a documented tachyphylaxis finding from a clinical trial.

Safety Profile and Regulatory Status

Known and Theoretical Risks

Neither peptide has a completed long-term safety study in humans. The central theoretical concern with any angiogenic and IGF-1-elevating combination is oncology risk. VEGF promotes tumor vascularization; IGF-1 has documented mitogenic effects on multiple cancer cell lines. [11] This does not mean the combination causes cancer; it means anyone with a personal or family history of hormone-sensitive malignancy, or an elevated baseline IGF-1, should not use these compounds outside a monitored clinical trial.

Ipamorelin at standard doses does not meaningfully raise fasting glucose in short-term animal studies, but IGF-1 elevation can increase insulin sensitivity transiently, which may affect diabetic or pre-diabetic individuals. [5] Water retention is reported anecdotally with GH-stimulating peptides at higher doses.

FDA and Regulatory Status

The FDA does not recognize either TB-500 or Ipamorelin as approved drugs for human therapeutic use. In March 2024, the FDA removed ipamorelin from the list of bulk drug substances eligible for compounding under 503A and 503B pathways, meaning compounding pharmacies in the United States cannot legally produce it for patient use. [12] Practitioners operating in this space after that ruling are doing so outside current FDA compounding regulations. TB-500 has never appeared on an FDA-approved drug list.

Patients should verify the current regulatory environment in their jurisdiction before obtaining or using either compound.

Monitoring Recommendations

Baseline and follow-up labs are the minimum reasonable standard for anyone using this stack in a supervised research or clinical context.

Key labs to track: serum IGF-1 (baseline, 6 weeks, end of cycle), fasting glucose and insulin, complete blood count, comprehensive metabolic panel, and C-reactive protein. IGF-1 should stay within age-adjusted normal ranges (roughly 115 to 307 ng/mL for adults aged 30 to 50 per the Endocrine Society reference intervals). [13] Values consistently above the upper limit of normal suggest excessive GH-axis stimulation and warrant dose reduction or discontinuation.